sbp-9330
Small moleculeexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2021 (NCT04948827)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Group II metabotropic glutamate receptor (mGlu2/mGlu3) inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04948827 | Phase 1 | Jul 20, 2021 | Camino Pharma, LLC, National Institute on Drug Abuse (NIDA), Sanford-Burnham Medical Research Institute, University of California, San Diego |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Camino Pharma, LLC | For profit | 1 | 1 | 1 | 2021 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2021 |
| Sanford-Burnham Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1